Pneumococcal Polysaccharide Vaccine (PPSV23) is a sterile, liquid vaccine containing purified capsular polysaccharide antigens from 23 serotypes of Streptococcus pneumoniae (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). Each 0.5 mL dose contains 25 mcg of each polysaccharide type, dissolved in isotonic saline solution containing 0.25% phenol as a preservative. It is indicated for active immunization against pneumococcal disease caused by the included serotypes, which account for approximately 85-90% of invasive pneumococcal disease in adults in India. It induces a T-cell independent B-cell response, leading to the production of opsonizing antibodies that enhance phagocytosis and clearance of the bacteria.
Adult: Single 0.5 mL dose, administered intramuscularly (preferably) or subcutaneously.
Note: Shake the prefilled syringe or vial well before use to form a homogeneous, cloudy white suspension. Inspect for particulate matter or discoloration. Administer by IM injection into the deltoid muscle or anterolateral thigh. For SC administration, inject into the fatty tissue over the triceps. Do not inject intravenously or intradermally. Do not mix with any other vaccine or product in the same syringe. Separate injection sites by at least 2.5 cm if administering with other vaccines.
The vaccine contains purified, high molecular weight capsular polysaccharides from the cell walls of 23 pneumococcal serotypes. Upon intramuscular or subcutaneous injection, these polysaccharide antigens are taken up by antigen-presenting cells (APCs) in the tissue and transported to lymphoid organs. They directly stimulate mature B-lymphocytes in a T-cell independent manner (Type 2 T-independent antigen). This leads to B-cell proliferation and differentiation into plasma cells, which produce serotype-specific IgG antibodies (primarily IgG2 subclass). These opsonizing antibodies bind to the bacterial capsule, facilitating phagocytosis and complement-mediated killing by neutrophils and macrophages, thereby preventing invasive disease.
Pregnancy: Category B2 (Australian categorization) / Not formally categorized by US FDA. Animal reproduction studies have not been conducted. It is not known if the vaccine can cause fetal harm. Use during pregnancy only if clearly needed, such as in women with high-risk medical conditions. Ideally, administer before pregnancy if possible. Inactivated vaccines are generally considered safe in pregnancy.
Driving: Vaccine is unlikely to affect the ability to drive or use machines. However, individuals should be advised about potential side effects like fever, malaise, or dizziness which could impair performance.
| Immunosuppressive Therapies | Corticosteroids (high-dose, prolonged), chemotherapy, radiation, biologics (e.g., anti-TNF agents, rituximab) can blunt the immune response to the vaccine, potentially reducing efficacy. | Major |
| Other Vaccines | Can be administered concurrently with inactivated influenza vaccine, COVID-19 vaccines, and other inactivated vaccines at different injection sites. No significant interaction. Concurrent administration with zoster vaccine (live) is acceptable but data is limited; if not concurrent, a 4-week gap is not required as PPSV23 is inactivated. | Minor |
| Warfarin/Anticoagulants | Increased risk of bleeding or hematoma from intramuscular injection. Consider subcutaneous administration or ensure proper technique and pressure post-injection. | Moderate |
| Pneumococcal Conjugate Vaccine (PCV13/PCV15/PCV20) | Sequential administration is recommended for certain high-risk adults. Administer PCV13/15 first, followed by PPSV23 at least 8 weeks later (for immunocompromised) or 1 year later (for others). If PPSV23 is given first, wait at least 1 year before giving PCV13/15. PCV20 can be given as a single dose without PPSV23 follow-up in many cases. | Major (if timing not followed, may blunt response to PCV) |
Same composition (Pneumococcal Polysaccharide Vaccine (25mcg)), different brands: